Summary
The steady state concentrations of glibenclamide in serum were measured radioimmunologically in 37 diabetic patients after administration for at least a year. No other antidiabetic drugs had been given. The interindividual variation in glibenclamide concentrations was extremely large (0 to 1520 nmol/l), greatly exceeding the variation in dosage (2.5–25 mg daily). There was no relation between dose and serum concentration of glibenclamide. Only four (9%) patients had fasting blood glucose concentrations below 5.5 mmol/l, and fewer than half had values below 8 mmol/l. In most cases, therefore, the therapy was inadequate. Single-dose kinetics of glibenclamide was assessed in healthy volunteers. Food intake did not influence the bioavailability of a 5 mg dose of glibenclamide. There was no insulin increase in response to glibenclamide unless a meal was also given, and this increase was not significant until 1 h after administration of drug and meal, when the mean serum concentration of glibenclamide had reached 100nmol/l. Even in the fasting state, however, there was a progressive fall in blood glucose after glibenclamide administration, significant within 45 min and with a nadir at 2–2 1/2 h.
Article PDF
Similar content being viewed by others
References
Shen, S.-W., Bressler, R.: Clinical Pharmacology of oral anti-diabetic agents (first of two parts). N. Engl. J. Med.296, 493–497 (1977)
Shen, S.-W., Bressler, R.: Clinical Pharmacology of oral anti-diabetic agents (second of two parts). N. Engl. J. Med.296, 787–793 (1977)
Melander, A., Sartor, G., Wåhlin-Boll, E., Scherstén, B., Bitzen, P. O.: Serum tolbutamide and chlorpropamide concentrations in patients with diabetes mellitus. Br. Med. J.1978 I, 142–144
Sartor, G., Scherstén, B., Melander, A.: Effects of glipizide and food intake on the blood levels of glucose and insulin in diabetic patients. Acta Med. Scand.203, 211–214 (1978)
Wåhlin-Boll, E., Sartor, G., Melander, A., Scherstén, B.: (in preparation)
Melander, A.: Influence of food on the bioavailability of drugs. Clin. Pharmacokinet.3, 337–351 (1978)
Hrtska, V. E., Schmidt, F. M.: Radioimmunologische Bestimmung von Glibenklamid (Abstract). 8. Kongress der deutschen Diabetes-Gesellschaft, München 1973
Coburn, H. J., Carrol, J. J.: Improved manual and automated colorimetic determination of serum glucose, with use of hexokinase and glucose-6-phosphate dehydrogenase. Clin. Chem.19, 127–130 (1973)
Wide, L., Axén, R., Porath, J.: Radioimmunosorbent assay for proteins. Chemical couplings of antibodies to insoluble Dextran. Immunochemistry4, 381–386 (1967)
Eshelman, F. N.: Drug compliance in diabetics (Letter to the Editor). Br. Med. J.1978 I, 581
Melander, A.: Drug compliance in diabetics (Letter to the Editor). Br. Med. J.1978 I, 990
Johnsson, G., Regårdh, C.-G.: Clinical pharmaçokinetics of β-adrenoceptor blocking drugs. Clin. Pharmacokinet.1, 233–263 (1976)
Alexandersson, B., Sjöqvist, F.: Interindividual differences in the pharmaçokinetics of monomethylated tricyclic antidepressants: role of genetic and environmental factors and clinical importance. Ann. N.Y. Acad. Sci.179, 739–751 (1971)
Lund, L.: Effects of phenytoin in patients with epilepsy in relation to its concentration in plasma. In: Biological effects of drugs in relation to their plasma concentrations. Davies, D. S., Pritchard, B. N. C. (Eds.), pp. 227–238. London: Macmillan 1973
Thomas, R. C., Ikeda, G. J.: The metabolic fate of tolbutamide in man and in the rat. J. Med. Chem.9, 507 (1966)
Rupp, W., Christ, O., Heptner, W.: Resorption, Ausscheidung und Metabolismus nach intravenöser und oraler Gabe von HB 419-14C an Menschen. Arzneim. Forsch.19, 1428–1434 (1969)
Schmidt, F. H.: Plasma levels and excretion of glibenclamide in renal insufficiency. Atti delle giornate di diabetologia del Mediterraneo, pp. 1–18. Milano: Boehringer Biochemia s.r.l. 1975
Widström, A., Cerasi, E.: On the action of tulbutamide in normal man. II. Modulation of glucose-induced insulin release by tolbutamide. Acta Endocrinol. (Kbh.)72, 519–531 (1973)
Grill, V., Cerasi, E.: Interacting effects of sulfonylureas and glucose on cyclic AMP metabolism and insulin release in pancreatic islets of the rat. J. Clin. Invest.61, 1346–1354 (1978)
Feldman, J. M., Lebovitz, H. E.: Appraisal of the extrapancreatic actions of sulfonylureas. Arch. Intern. Med.123, 314 (1969)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sartor, G., Melander, A., Scherstén, B. et al. Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. Diabetologia 18, 17–22 (1980). https://doi.org/10.1007/BF01228296
Received:
Revised:
Issue Date:
DOI: https://doi.org/10.1007/BF01228296